Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
NCT06620003 is registered in ClinicalTrials.gov with Albert B. Sabin Vaccine Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
- Lead sponsor
- Albert B. Sabin Vaccine Institute
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 14, 2025
- Completion date
- October 31, 2026
- Enrollment
- 200 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.